Company intelligence / Profile preview
Okklo Life Sciences
Nijmegen, Gelderland, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
Okklo Life Sciences is developing proprietary cyclodextrin-based therapeutics for rare metabolic, hematologic, and immunologic diseases; available public information indicates preclinical development without reported human clinical trial data yet.[2][3][4][9]
- Therapeutic areas
- HematologyImmunologyPulmonologyRare Diseases
- Modalities
- Small moleculeNanoparticlePolymer-drug conjugate therapyHydrogel-based drug delivery therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sanquin (joint research leading to OKL-1111, later spun into Alveron Pharma)[6]
Beyond the preview
Go deeper on Okklo Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Okklo Life Sciences.